Page 8 - Priority Review News Today

AstraZeneca plc and Daiichi Sankyo's Enhertu has gained US approval for treating HER2-positive solid tumours, marking a significant advancement in cancer treatment.

– Consistent safety and efficacy profiles across adult and pediatric populations –

TARRYTOWN, N.Y., April 07, 2024 -- Regeneron Pharmaceuticals, Inc. today announced the oral plenary session presentation of positive pivotal data from the Phase 1/2 LINKER-MM1 trial of...

Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration and European Medicines Agency TARRYTOWN, N.Y., April 07, 2024 -- Regeneron...

Press Release ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Apr 5, 2024--

Based on three Phase II trials of AstraZeneca and Daiichi Sankyos Enhertu which showed clinically meaningful responses across a broad range of tumours ...

The U.S. Food and Drug Administration has approved Basilea Pharmaceutica International Ltd.'s new Zevtera Antibiotic (ceftobiprole medocaril sodium for injection) for three different bacterial infections.

Cash and cash equivalents totaled €77.8 million as of December 31, 2023Revenues amounted to €28.6 million as of December 31, 2023 including a milestone payment of €13.3 millionTopline interim...

Data highlighted in oral presentation at World Vaccine Congress 2024 on April 3, 2024 Early data from patients eligible for evaluation at week 12 show two observations of stable disease,...